Akeso's Gumokimab Monoclonal Antibody (IL-17) New Drug Application for the Treatment of Moderate to Severe Psoriasis Accepted by NMPA ...Middle East

HONG KONG, Jan. 26, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the New Drug Application (NDA) of its internally-developed IL-17-targeting monoclonal antibody gumokimab (AK111) has been accepted by the Center for Drug Evaluation (CDE)...

Hence then, the article about akeso s gumokimab monoclonal antibody il 17 new drug application for the treatment of moderate to severe psoriasis accepted by nmpa was published today ( Monday 27/01/2025 - 05:00 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Akeso's Gumokimab Monoclonal Antibody (IL-17) New Drug Application for the Treatment of Moderate to Severe Psoriasis Accepted by NMPA )

Also on site :

• Vue Cinema Chain Halts Liquidation Threat From Coca-Cola Bottling Giant After Settling Unpaid Bill
• ‘90s Rocker Announces Book Tour in Support of ‘Refreshingly Pure of Heart’ Memoir
• 'Dancing With the Stars' Tour Forced to Reschedule Show Due to Impending Snowstorm